Review

Abnormal Expression of Mitochondrial Ribosomal Proteins and Their Encoding Genes with Cell Apoptosis and Diseases

Guomin Huang 1,2,3,4,5,†, Hongyan Li 1,2,3,4,5,† and Hong Zhang 1,2,3,4,5,*

1 Department of Medical Physics, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China; huangguomin@impcas.ac.cn (G.H.); liby@impcas.ac.cn (H.L.)
2 Advanced Energy Science and Technology Guangdong Laboratory, Huizhou 516029, China
3 Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou 730000, China
4 College of Life Sciences, University of Chinese Academy of Sciences, Beijing 101408, China
5 School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 101408, China
* Correspondence: zhangh@impcas.ac.cn; Tel.: +86-0931-4969344
† Contributed equally to this work.

Received: 16 October 2020; Accepted: 17 November 2020; Published: 23 November 2020

Abstract: Mammalian mitochondrial ribosomes translate 13 proteins encoded by mitochondrial genes, all of which play roles in the mitochondrial respiratory chain. After a long period of reconstruction, mitochondrial ribosomes are the most protein-rich ribosomes. Mitochondrial ribosomal proteins (MRPs) are encoded by nuclear genes, synthesized in the cytoplasm and then, transported to the mitochondria to be assembled into mitochondrial ribosomes. MRPs not only play a role in mitochondrial oxidative phosphorylation (OXPHOS). Moreover, they participate in the regulation of cell state as apoptosis inducing factors. Abnormal expressions of MRPs will lead to mitochondrial metabolism disorder, cell dysfunction, etc. Many researches have demonstrated the abnormal expression of MRPs in various tumors. This paper reviews the basic structure of mitochondrial ribosome, focuses on the structure and function of MRPs, and their relationships with cell apoptosis and diseases. It provides a reference for the study of the function of MRPs and the disease diagnosis and treatment.

Keywords: mitochondrial ribosome; mitochondrial ribosomal proteins; apoptosis; cancer; mitochondrial disease; biomarker

1. Introduction

Ribosome is the ribonucleoprotein particle, which is an organelle for protein synthesis in cells, and its function is to synthesize the polypeptide chain efficiently and accurately according to the information of mRNA. Ribosomes can be found in almost all cells and even the smallest and simplest mycoplasma cell contains hundreds of them. At present, only mammalian mature red blood cells have no ribosomes, therefore, ribosomes are an indispensable structure of most cells. Mitochondria and chloroplasts contain ribosomes that synthesize their own proteins, which may be related to the origin of mitochondria and chloroplasts. The accepted endosymbiotic origin theory holds that mitochondria and chloroplasts originated from symbiotic bacteria and cyanobacteria in primitive eukaryotic, respectively. Therefore, mitochondrial ribosomes are more similar to the bacterial ribosomes than to cytoplasmic ribosomes. Mitochondrial ribosomal proteins (MRPs) are encoded by nuclear genes and synthesized by the cytoplasm 80S ribosomes, after specific targeting, sorting, transporting to mitochondria, and then assembling into mitochondrial ribosome small and large subunits with two
rRNAs encoded by mitochondrial DNA (mt-DNA). With the research on MRPs, their names have changed [1], as shown in Table 1. The table also shows the changes of MRPs in tumor tissues reported in the past 5 years.

**Table 1.** Summary of the relationship between abnormal expression of mitochondrial ribosomal proteins and their encoding genes with diseases in recent 5 years.

| Old Name | New Name | Cancer                                                                 | Other Diseases                                                                 |
|----------|----------|----------------------------------------------------------------------|--------------------------------------------------------------------------------|
| MRPL1    | uL1m     | Mitochondrial ribosomal large subunit (mt-LSU) genes and proteins.    |                                                                                 |
| MRPL3    | uL3m     | MRPL3 uL3m                                                           | Lung cancer [2]                                                                 |
| MRPL9    | bL9m     | Breast cancer [8]                                                    |                                                                                 |
| MRPL10   | uL10m    | Early age-related macular degeneration [9]                           |                                                                                 |
| MRPL11   | uL11m    | Mitochondrial encephalopathy [10]                                    |                                                                                 |
| MRPL12/L7| bL12m    | Breast cancer [11] †, Colorectal cancer [12]                         |                                                                                 |
| MRPL13   | uL13m    | Liver cancer [13] †, Breast cancer [13–15] †                       |                                                                                 |
| MRPL15   | uL15m    | Breast cancer [16] †                                                 |                                                                                 |
| MRPL16   | uL16m    | Septic cardiomyopathy [17] †                                         |                                                                                 |
| MRPL17   | bL17m    | Lung cancer [18] †                                                   |                                                                                 |
| MRPL19   | bL19m    | Endometrial cancers [19,20], Diffuse non-Hodgkin lymphoma [21], Melanoma [22] |                                                                                 |
| MRPL21   | bL21m    | Acute myeloid leukemia [23] †                                        |                                                                                 |
| MRPL23   | uL23m    | Oral squamous cell carcinoma [24] †, Glioblastoma multiforme [25]    |                                                                                 |
| MRPL24   | uL24m    | Cerebellar atrophy, intellectual disability [26] †                  |                                                                                 |
| MRPL28   | bL28m    | Gastric cancer [27]                                                  |                                                                                 |
| MRPL33   | bL33m    | Breast cancer [28] †, Lung cancer, colon cancer [29] †, Gastric cancer [30], Acute myeloid leukemia and neuroblastoma [31] †, Human papillomavirus associated oropharyngeal squamous cell carcinoma [32] † |                                                                                 |
| MRPL34   | bL34m    | Cardiomyocyte hypertrophy [33] †                                     |                                                                                 |
| MRPL35   | bL35m    | Glioblastoma multiforme [34] †, Colorectal cancer [35] †            |                                                                                 |
| MRPL36   | bL36m    | Cri-du-chat syndrome [36]                                            |                                                                                 |
| MRPL37   | mL37     | Venous thromboembolism [37]                                          |                                                                                 |
| MRPL38   | mL38     | Liver cancer [38]                                                   |                                                                                 |
| MRPL39   | mL39     | Gastric cancer [39] †                                                |                                                                                 |
| MRPL40   | mL40     | Schizophrenia [40–42] †                                              |                                                                                 |
| MRPL42   | mL42     | Glioma [43] †                                                       |                                                                                 |
| MRPL43   | mL43     | Gastric cancer [44] †                                                |                                                                                 |
| MRPL44   | mL44     | Mitochondrial encephalopathy [10] †, Cardiomyopathy [45,46], Hemiplegia migraine, pigmentary retinopathy, renal insufficiency, Leigh-like lesions on brain MRI [47], Asthma and allergy-related traits [48] |                                                                                 |
Table 1. Cont.

| Old Name | New Name | Cancer | Other Diseases |
|----------|----------|--------|----------------|
| MRPL46   | mL46     | Ovarian cancer [49] |
| MRPL47   | mL47     | Acute lymphoblastic leukemia [50] |
| MRPL50   | mL50     | Cardiomyocyte hypertrophy [33] ↑ |
| MRPL51   | mL51     | Lung cancer [51] ↑ |
| MRPL52   | mL52     | Colorectal cancer [52] ↓ |
| MRPL54   | mL54     | Breast cancer [53] |
| CRIF1    | mL64     | Hepatocellular carcinoma [54] ↓, T-cell leukemia [55] ↑, Acute radiation syndrome [56], Endothelial inflammation [57,58], Autoimmune arthritis [59] ↑ |
| MRPS18-A | mL66     | Liver cancer [60] ↑, Cholangiocarcinoma [61] ↑ |
|          |          | Mitochondrial ribosomal small subunit (mt-SSU) genes and proteins |
| MRPS2    | uS2m     | Glioblastoma multiforme [25] | Cardiomyocyte hypertrophy [33] ↑ |
| MRPS5    | uS5m     | Noise-induced hearing loss and anxiety related behavior changes [62] ↑ |
| MRPS7    | uS7m     | Osteosarcoma [63] ↑ | Primary hypogonadism, primary adrenal failure [64] ↓ |
| MRPS11   | uS11m    | Uveal melanoma [65] ↑ |
| MRPS12   | uS12m    | Glioblastoma multiforme [25] |
| MRPS14   | uS14m    | Perinatal hypertrophic cardiomyopathy [66] ↑ |
| MRPS18-B | mS40     | Prostate cancer [67] ↑, Colorectal carcinoma [68] | Tuberculosis [69] |
| MRPS18-C | bS18m    | Breast cancer [70] ↑ | Epileptic encephalopathy [71] |
| MRPS21   | bS21m    | Cardiomyocyte hypertrophy [33] ↑ |
| MRPS22   | mS22     | Epicantus inversus syndrome [72], Hypertrophic cardiomyopathy and fallopian tube lesions [73] ↓, Primary ovarian insufficiency [74–76] |
| MRPS23   | mS23     | Hepatocellular carcinoma [77] ↑ |
| MRPS34   | mS34     | Glioblastoma multiforme [25] | Cardiomyocyte hypertrophy [33] ↓ |
| MRPS37   | mS37     | Acute lymphoblastic leukemia [23] ↑ |
| MRPS39   | mS39     | Leigh syndrome [78] |

Legend: Prefix “u”: Genes and proteins are present in all kingdoms of life (for universal); prefix “u”: Genes and proteins are bacterial in origin and do not have an eukaryotic (or archaeal) homolog; prefix “m”: Genes and proteins are mitochondrion-specific. ↑ “↑” Upregulation in that disease; ↓ “↓” downregulation in that disease. This table only lists the MRPs (mitochondrial ribosomal proteins) that appear in this article.

In this paper, we will introduce the basic structure of mitochondrial ribosomes and emphasize the significance of MRPs in mitochondria. Some of the MRPs can participate in cell apoptosis as apoptosis-inducing factors or play a functional role in the process of tumorigenesis. We will highlight the relationship between MRPs and diseases, and the important influence of MRPs as molecular markers in relevant fields.

2. MRPs on Structure and Function of Mitochondrial Ribosomes

The mitochondrial ribosome is an irregular granular structure without biofilm encapsulation, its main components are RNA (account for two-thirds) and proteins (account for one-third). Protein is mainly distributed on the surface of ribosomes and RNA is mainly located in the interior, they are held together by non-covalent bonds. The mitochondrial ribosome is 25–30 nanometers in size and contains two different subunits, mt-LSU and mt-SSU. The mt-SSU is made of 12S rRNA and 30 MRPs, the mt-LSU consists of 16S rRNA, mt-tRNAVal, and 50 MRPs. The 12S rRNA and 16S rRNA are transcribed from the mt-DNA gene and 36 of the 80 proteins are specific to the mitochondria. The overall structure of mt-SSU is elongated and divided into three areas: head, platform, and foot (Figure 1). The head region is characterized by the presence of MRPS29 and the foot region is characterized by the pentapeptide...
Another obvious di-

highlight the relationship between MRPs and dise-
as, and the... part may be replaced by MRPL5, which connects the mt-SSU and head doma-

ins to form a latch across the mRNA channel.

The mt-SSU provides a platform for mRNA binding and decoding, while mt-LSU catalyzes the peptide-transferase reaction. The A-site residues contributed by the mt-SSU are important for decoding proteins, whereas only a few participate in filling the space of the deleted rRNA [79,86].

The abundance of respiratory complexes and the activity of cytochrome C oxidase [90].

tRNA. Additionally, this protein is necessary for mitochondrial translation since knocking it out reduces shrunken mitochondria [89]. The foot signature protein (MRPS27) is associated with 12S rRNA and through MRPS29, which is the signature protein of the mt-SSU head and its deficiency results in extending the conserved ring. Only mitochondrial ribosomes acquire an intrinsic GTPase activity at the entry site, they lack protein MRPL4 and a domain of MRPL3 compared with bacteria. This missing part may be replaced by MRPL5, which connects the mt-SSU and head domains to form a latch across the mRNA channel [85] (Figure 2). The protein function of mitochondrial ribosomes is conserved. However, the mammalian mitochondrial ribosomes have substantial differences in both the entry and exit sites of this channel compared to other ribosomes. At the entry site, they lack protein MRPL4 and a domain of MRPL3 compared with bacteria. This missing part may be replaced by MRPL5, which connects the mt-SSU and head domains to form a latch across the mRNA channel [85]. The mRNAs enter the channel entrance as a single strand and bind to PTCD3 (MRPS39), the largest protein of the mt-SSU. In addition, MRPS39 knockdown results in a significant overall decrease in mitochondrial protein synthesis [87]. During translation initiation, the 3′ end of rRNA is stably associated with MRPS37 [88].

Another obvious difference is the polypeptide exit tunnel. Generally, the exit region of the tunnel is defined by a conserved ring of proteins (MRPL22, MRPL23, MRPL24). However, in mammals, a second layer of additional mitochondrial specific proteins (MRPL39, MRPL44, MRPL45) are found extending the conserved ring. Only mitochondrial ribosomes acquire an intrinsic GTPase activity through MRPS29, which is the signature protein of the mt-SSU head and its deficiency results in shrunked mitochondria [89]. The foot signature protein (MRPS27) is associated with 12S rRNA and tRNA. Additionally, this protein is necessary for mitochondrial translation since knocking it out reduces the abundance of respiratory complexes and the activity of cytochrome C oxidase [90].

![Figure 1. Mitochondrial ribosomes are composed of mt-SSU and mt-LSU. The overall structure of mt-SSU is divided into three areas: head, platform, and foot. The head region is characterized by the presence of MRPS29 and the foot region is characterized by MRPS27.](image-url)
while AKT opposes the pro-apoptotic action of MRPS29 [99].

Three MRPs associated with apoptosis have been identified, namely, MRPS29 (DAP3), MRPL41 (BMRP), and MRPS30 (mL65).

### 3.1. MRPS29 (DAP3)

MRPS29, also known as death-associated protein 3 (DAP3), is a GTP-binding protein and a head marker of mt-SSU [91]. MRPS29 contains three potential structural motifs for GTP binding, including the phosphate binding P-loop motif, which is essential for MRPS29-induced cell death [92]. Therefore, MRPS29 is involved in the alterations of the mitochondrial network dynamics that occur during apoptosis, cell death, and mitochondrial rupture [89,93]. A high expression of MRPS29 promotes apoptosis [94]. MRPS29 has been found on the outside of mitochondria to initiate the extrinsic apoptotic pathway through its interactions with apoptotic factors such as Fas ligand, tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) [95]. In this process, MRPS29 does not have to be released from the mitochondria to perform its cell death function [96]. DAP3 binds directly to the death domain of TNF-related apoptosis-inducing ligand (TRAIL) receptors. Moreover, DAP3 associates with the pro-caspase-8–binding adapter protein Fas-associated death domain (FADD), and links FADD to the TRAIL receptors, DR4 and DR5 [97,98]. Furthermore, MRPS29 is a substrate of the kinase AKT (PKB), while AKT opposes the pro-apoptotic action of MRPS29 [99].

### 3.2. MRPL41 (BMRP)

MRPL41 has also been named BMRP (Bcl-2 interacting mitochondrial ribosomal protein) [100]. In the structure of the mt-LSU, MRPL41 has most of the extended conformation and interacts with 16S rRNA and several surrounding MRPs, including another pro-apoptotic protein, MRPL65 [84].

MRPL41 could perform the function of binding and participating in the regulation of the PTP/Bcl-2 mitochondrial complex. It is released from the mitochondria and interacts with both the BH4 domain and the central region encompassing BH1, BH2, and BH3 domains of Bcl-2, rather than initiating...
apoptosis in the mitochondria [100,101]. The cell death induced by MRPL41 is also inhibited by the caspase inhibitor p35, suggesting that BMRP induces apoptosis by a mechanism mediated by caspases, which can be blocked by Bcl-2 or the baculoviral caspase inhibitor p35 [100]. Additionally, overexpression of MRPL41 enhances the p53 stability and makes it translocated to the mitochondria, therefore, contributing to the p53-induced apoptosis (via transcription independent mechanisms) in response to growth-inhibitory conditions [102]. In the absence of p53, MRPL41 has also been shown to mediate a serum starvation-induced cell cycle arrest through an increase of p21WAF1/CIP1 and p27Kip1 protein levels, revealing that MRPL41 can induce apoptosis through the p53-independent pathway [103].

3.3. MRPL65 (PDCD9, MRPS30)

MRPL65 was also known as PDCD9 (programmed cell death protein 9) or MRPS30, it was originally considered to be a small subunit protein. But it was later observed to appear on the large subunit, and therefore, renamed mL65 [92]. Overexpression of mrpl65 in mouse fibroblasts can induce apoptosis by upregulating transcription factors c-Jun and activating the c-Jun N-terminal kinase 1 (JNK1) [104]. However, little is known overall about the molecular mechanisms underlying the pro-apoptotic roles of mL65 up to now.

4. MRPs Associated with Cancers

Scientists explored the new mutations, epigenetic disorders, abnormal genes expression and protein abundance patterns based on genomics and proteomics, which establish causal relationships between MRPs abnormalities and carcinogenesis or provide diagnostic and therapeutic markers in some cases [2,105]. Based on additional experimental results, the same MRPs may affect multiple cancers and multiple MRPs abnormalities can be detected in the same cancer, which forms a complex and changeable network system. MRPs may be used as markers for the detection of the development of various cancers. However, the specific mechanism of MRPs-induced cancer is still lacking, and the way in which they play a role in cancer needs to be further explored.

4.1. MRPs and Breast Cancer

The most widespread concern is the relationship between MRPs and breast cancer. Genome-wide association studies (GWASs) have revealed an increased breast cancer risk, which is associated with multiple genetic variants in 5p12 [106]. The risk allele, rs4415084-T, is highly correlated with the MRPS30 expression level through a new method combining a quantitative expression trait locus analysis and allele-specific expression analysis in the 5p12 breast cancer susceptibility region [107]. Based on another evidence, the 5p12 variant, rs10941679, was regulated by FGF10 and MRPS30 to increase susceptibility to estrogen receptor positive breast cancer [106]. These ideas have been tested to a certain extent, using luciferase reporter assays in both estrogen-receptor positive (ER+) and negative (ER-) cell lines. Guo et al. showed that alternative alleles of potential functional single-nucleotide polymorphisms (SNPs), rs3747479 (MRPS30), could significantly change promoter activities of their target genes compared to reference alleles. MRPS30 plays a crucial role in the development of breast tumors in vitro [108]. MRPS30-DT (the long non-coding RNA, lncRNA) knockout significantly inhibits the proliferation and invasion of breast cancer cells, and induces cells apoptosis [109]. In addition to the 5p12 site, a new breast cancer susceptibility site was identified in 4q21 (rs11099601). An expression quantitative trait locus (QTL) analysis in breast cancer tissue showed that rs11099601 is associated with MRPS18-C [70].

In the process of exploring the relationship between mitochondrial biogenesis related nuclear coding genes and breast cancer recurrence, distant metastasis and prognosis, twelve different components of large subunit proteins showed a significant prognostic value, among which MRPL15 had the best prognostic value [16]. Similarly, the bioinformatics analysis found that MRPL13 may have a prognostic value for breast cancer, the survival rate of breast cancer patients with a high
expression of MRPL13 was relatively low, which could be used as a potential prognostic marker for breast cancer [13–15]. MRPL33, a protein in mt-LSU, is linked with breast cancer metastasis through RNA depth sequencing (RNA-seq) analysis and the content of MRPL33 exon 3 was significantly increased in breast cancer, lung cancer, colon cancer, etc. [28]. The isoform-specific knockdown of exon 3-containing MRPL33 mRNA (MRPL33-L) inhibits cancer cell growth and considerably induces cell death. The mechanism analysis showed that MRPL33 exon 3 could be regulated by multiple splicing factors including the hnRNPK protein. The hnRNPK and MRPL33-L are required for a normal mitochondria function in cancer cells, as both depletion of them led to reduced levels of 16S rRNA and caused excessive reactive oxygen species (ROS) production and insufficient ATP generation [29]. In a recent study on the prediction and classification of breast cancer proteins, MRPL54 is one of the RNA-binding proteins associated with breast cancer [8]. A new logistic regression model to classify breast cancer tumor samples based on microarray expression data was introduced in some papers, which illustrated that those genes, such as MRPL9, exhibit oncogenic characteristics and may be potential breast cancer predictors [8]. Moreover, Zhang et al. also found that MRPL12 expression is upregulated in cancerous stromal cells compared with the cells in a normal breast tissue [11].

Several MRPs are associated with breast cancer, which are either differentially expressed specifically in breast cancer or interact with the breast cancer susceptibility gene loci to promote or inhibit the development of breast cancer. However, no clear pathway shows how MRPs play role in breast cancer. Subsequent studies would further explore the specific mechanisms of MRPs affecting breast cancer.

4.2. MRPs and Digestive Tract Cancers

Cancers of the digestive tract mainly include malignant tumors of the throat, esophagus, liver, gallbladder, pancreas, large and small intestines. With abundant achievements in the past 5 years, the relationship between MRPs and digestive tract cancer has been gradually revealed.

LncRNA MRPL23 antisense RNA1 (MRPL23-AS1) is implicated in different cancers by an increasing microvascular permeability and promoting the metastasis of salivary adenoid cystic carcinoma in vivo, which also plays a role in the regulation of oral squamous cell carcinoma [24,110]. MRPL33 has also been shown to be significantly associated with the human papillomavirus associated oropharyngeal squamous cell carcinoma [32].

Liver cancer is the fourth most common cancer in China. Therefore, the relationship between the development of liver cancer and MRPs has received much attention and was relatively clarified. In hepatocellular carcinoma, the decreased expression of MRPL13 is a key factor in the regulation of mitochondrial ribosome and subsequent OXPHOS (oxidative phosphorylation) deficiency, which regulated the aggressive activity of liver cancer cells [13]. However, MRPS23 overexpression was found to promote hepatocellular carcinoma cell proliferation and suggested a low survival rate in hepatocellular carcinoma patients [77]. Similar to MRPS23, the increase of MRPS18-A can promote the development of liver cancer [60]. According to the Pearson correlation analysis of the construction module and clinical traits, gene MRPS18-A affects not only the liver function but also the overall survival of patients with cholangiocarcinoma [61]. The CR6 interaction factor 1 (CRIF1, MRPL64) inhibits invasiveness by inhibiting TGF-β mediated epithelial mesenchymal transition in hepatocellular carcinoma [54]. Exon sequencing was performed on liver cancer samples using next-generation sequencing technology, the results indirectly proved that MRPL38 was highly expressed in liver cancer [38].

Gastric cancer is the third most common cancer in China, which harms many people’s lives and health. If a reliable link can be found between MRPs and gastric cancer, it will provide a powerful help for the treatment of gastric cancer. In the treatment of gastric cancer with epirubicin, the MRPL33-short isomer (MRPL33-S) and MRPL33-long isomer (MRPL33-L) showed opposite effects. MRPL33-S promoted the sensitivity of gastric cancer cells to epirubicin, while the splicing variant MRPL33-L inhibited this effect. The upregulated MRPL33-S could promote the chemotherapy response of gastric cancer cells to epirubicin, whereas MRPL33-L suppressed the chemotherapy response [30]. Sotgia et al.
interrogated 5-year follow-up data collected from a group of \(N=359\) gastric cancer patients and combined MRPL28 and other eight mitochondrial proteins to generate a compact gastric mitochondrial gene signature [27]. Another study has represented that MRPL39 serves as a tumor suppressor by directly targeting miR-130 in gastric cancer, suggesting that it may be a new gastric cancer biomarker for diagnosis and prognosis [39]. The expression level of MRPL43 in gastric cancer tissues is significantly upregulated. However, no obvious difference is seen in colorectal carcinoma (CRC), lung cancer and papillary thyroid cancer [44].

The incidence of colorectal cancer in China is only next to lung cancer. CRIF1 (MRPL64) enhanced the p53 activity in HCT116 colon cancer cell lines through chromatin remodeling SNF5, thereby inhibiting cell growth and tumor development [111]. MRPL12 as a downstream gene of c-Myc participates in the cetuximab resistance in RAS wild-type colorectal cancer (Caco2-CR) cells [12]. MRPS18-2 may be a biomarker for CRC based on the analysis of the genetic polymorphism of Gly132Cys in clinical CRC samples and surrounding normal tissues. However, the function of this polymorphism and potential of MRPS18-2 as a CRC biomarker still needs to be assessed [68]. In addition, mrpl35 is upregulated in CRC and regulates the growth and apoptosis of CRC cells, which may be a potential therapeutic target for CRC [35]. MRPL32 is able to significantly predict the survival of patients with CRC, which is downregulated in the poor survival colorectal cancer sample [52].

In fact, there are numerous studies on the relationship between MRPs and digestive tract cancer, some of the explorations have been done in the last 5 years. As mentioned above, MRPL23 not only promotes the metastasis of salivary adenoid cystic carcinoma, it is also related to the occurrence of liver cancer [112], suggesting that the same MRP can affect different cancers. However, it is not clear whether there is a difference in the mechanism of its influence. In the future, understanding the abnormal expression of different MRPs in the same cancer or a particular MRP in different cancers, would be of great help to the research of new treatment regimens.

4.3. MRPs and Other Cancers

Lung cancer development, with its high morbidity and mortality, is associated with an abnormal expression of MRPs. Mauithed et al. used bioinformatic analysis and pharmacology experiments to verify the underlying regulatory mechanisms of MRPs on lung cancer and found a more than 5-fold increase in MRPL51 expression in a lung cancer cell model [51]. A new periodic mutation MRPL1 (Tyr87Cys) was found in asbestos-induced lung cancer patients but not in normal samples [2]. Academics screened the differentially expressed mitochondrial ribosomal genes between iAs (inorganic arsenic)-treated lung cancer cells and controls. Based on microarray data analysis, they identified four ribosomal genes similar to MRPL17 as key genes for prognosis of lung cancer [18]. A recent study found that MRPS16 promoted the growth, migration, and invasion of glioma cells by activating PI3K/AKT nail axis, these processes can be eliminated by knocking down MRPS16 and similar trends are observable in U251 and A172 cells after deletion of MRPL42 [43,113]. However, the high expression of MRPL35 can predict the longer survival of glioblastoma multiforme [34]. Benzyl isothiocyanate (BITC) inhibits several mitochondrial ribosomal genes including MRPS28, MRPS2, MRPL23, MRPS12, MRPL12 and MRPS34, suggesting that these genes may be potential biomarkers for the treatment of glioblastoma by BITC [25].

In cancers of the blood system, MRPL33 affects the receptor tyrosine kinase TrkA or KIT expression levels in acute myeloid leukemia (AML) and neuroblastoma, which has a prognostic value for both types of cancer [31]. In the study of the first recurrence of AML patients, AML cells were significantly characterized by increased levels of mitochondrial functional important proteins such as MRPL21 and MRPS37, which may guide treatment strategies to reduce the chemotherapeutic resistance to recurrent AML [23]. Additionally, MRPL49 is also associated with AML prognosis [114]. MRPL47 variation is a risk factor for vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia [50]. For diffuse non-Hodgkin lymphoma, MRPL19 is one of the related genes and the geometric mean of its expression can be used to normalize gene expression in melanoma [21,22].
MRPs have a significant effect in female-specific cancers. MRPL19 is one of the internal reference genes for type I or II endometrial cancers and the expression level of MRPL46 had the greatest influence on the prognosis of ovarian cancer [19,20,49]. Overexpression of MRPS18-B (MRPS18-2) leads to the epithelial cells that acquire a higher migration ability to transform as mesenchymal cell (EMT). Further studies have shown that MRPS18-2 induces EMT through the TWIST2/E-cadherin signal and CXCR4 (PC3 cells express the chemokine receptor) mediates the migration of prostate cancer cells [67]. Lately, MRPS7 was detected as a key gene in the pathophysiological process of osteosarcoma and the MRPL3 content is positively correlated with the prognosis of osteosarcoma [6]. Through a bioinformatics analysis such as gene ontology, MRPS11 was found to be overexpressed in uveal melanoma and is a potential prognostic indicator for uveal melanoma [65].

5. MRPs Associated with Diseases Except Cancers

MRPs genes are located at chromosomal sites and associated with a variety of human mitochondrial diseases. Mutations of MRPs genes can lead to diseases of varying degrees since the mitochondria cannot maintain a normal metabolic function. Changes in MRPs expression inhibits the mitochondrial genetic material translation (mainly mitochondrial respiratory chain protein synthesis) that destroys the mitochondrial ribosome composition, leading to mitochondrial diseases. In addition, MRPs can also act directly in some mitochondrial diseases through their own function changes. The defects in mt-DNA transcription and translation are associated with numerous classical mitochondrial diseases including mitochondrial encephalopathy, Leigh syndrome, mitochondrial neuro-gastro-intestinal encephalomyopathy, Pearson syndrome, etc. [46], which are closely related to the failure of mitochondria to maintain a normal metabolic function.

5.1. MRPs Associated with Mitochondrial Diseases

The deletion of MRPL10 can reduce the mitochondrial activity and expression of the mitochondrial complex, suggesting that MRPL10 is necessary for mitochondrial protein synthesis and mitochondrial activity. Moreover, the deletion of MRPL10 inhibits the kinase activity of cyclin-dependent kinase CDK1 and promotes mitochondrial fusion through dephosphorylation of Drp1Ser616, thereby affecting adaptive metabolic response, cell proliferation, and cell survival [115]. By analyzing the genomes of 142 patients with complex defects in the mitochondrial respiratory chain, MRPS23 was confirmed to be one of the genes responsible for the defect of the mitochondrial respiratory chain complex [116]. In addition, human MRPS34 mutations lead to Leigh or Leigh-like syndrome by destabilizing the mt-SSU and impairing mitochondrial protein translation [117]. Similarly, MRPS5 mutation affects the accuracy of mitochondrial ribosome assembly, leading to stress-related behavioral changes. Moreover, there is evidence that the homozygous mutant mrps5 V338Y mice was sensitive to noise since hearing loss and anxiety related behavior changes [62]. CRIF1 (MRPL64) is a very important component of the mt-LSU. The conditional knockout of crif1 (mrpl64) in specific tissues (such as brain, heart, intestine and adipose tissues) of mice induces mitochondrial dysfunction, resulting in epidermal damage skin homeostasis and hair morphogenesis [118]. The skeletal muscle deficiency of crif1 (mrpl64) induces progressive mitochondrial OXPHOS dysfunction and UPRmt activation, eventually resulting in late muscular dystrophy and sarcopenia [119]. In the study, regarding whether and how the lymphocyte-specific protein tyrosine kinase (Lck) promotes the metabolic transfer of T-cell leukemia through mitochondrial localization, mitochondrial Lck interferes with the mitochondrial translation mechanism by competitive binding to CRIF1 (MRPL64) [55]. Furthermore, the crif1 (mrpl64) deficiency promotes endothelial inflammation by downregulating SIRT1 and inducing vascular inflammation [57,58]. In mice with an impaired mitochondrial oxidative function of macrophages, a bone marrow-specific loss of crif1 (mrpl64) gene function causes systemic insulin resistance and lipo-inflammation [120]. In addition to crif1 (mrpl64), the mutation of mrpl20 was most pronounced in TALLYHO/Jng (TH) mice (the mice mimics many characteristics of human non-insulin-dependent type II diabetes mellitus) and may alter the folding, structure, and activity of the protein, as well as the ability
of mrpl20 to interact with other MRPs in the mitochondrial ribosome [121]. These redundant residues lead to an impaired mitochondrial biogenesis and abnormal OXPHOS. Therefore, mrpl20 is a key gene, which induces defective mitochondrial protein synthesis in TH mice [121]. In addition, mrps23, mrpl27, mrpl45 and mrpl48 mRNA levels are observed to be elevated in the heart and decreased in the liver of rats with metabolic syndrome [122]. The structural variation of mrpl3 induces neurodegeneration and memory impairment in adult mice [3].

5.2. Clinical Manifestations of MRPs Related Mitochondrial Disease

MRPs are associated with a range of mitochondrial diseases, in which clinical manifestations are complex. A homozygous mutation of MRPS22 was detected in a prepubertal woman with blepharophimosis, ptosis and epicanthus inversus syndrome (BPEs), resulting in a soft palate cleft and microcephaly other than the BPEs phenotype [72]. Homozygous mutations in MRPS7 were associated with primary hypogonadism, primary adrenal failure, sensorineural deafness, as well as lactic academia [64]. Likewise, biallelic mutations in MRPS2 also caused sensorineural hearing loss, hypoglycemia and multiple OXPHOS complex defects [123]. In a Japanese patient with Leigh syndrome, the mutations of the biallelic PTCD3 (MRPS39) resulted in frameshift changes and generated premature stop codons. Moreover, the loss function of PTCD3 resulted in translation defects in the mt-DNA encoding protein, accompanied with OXPHOS deficiency and destabilization of the mt-SSU. These findings suggested that PTCD3 mutations are related to mitochondrial ribosomal protein defects, causing neurodegenerative disease and premature death [78].

A homozygous missense mutation of MRPL24 was detected in one female infant with cerebellar atrophy, limb or facial arrangement and intellectual disability. In addition, complex I and IV defects were found in her muscle biopsy [26]. The regulation of MRPS18-C (encoding bS18m protein) expression might be an effective treatment strategy through studying fibroblasts from an epileptic encephalopathy patient with the m.3946G>A mutation in the mt-ND1 gene [71]. Significant reductions in MRPL11 and MRPL44 expression were found in the fibroblasts of another female infant with symptoms of mitochondrial encephalopathy, such as neonatal-onset seizures, microcephaly, pachygyria, progressive white matter atrophy and cortical blindness [10]. A few studies have reported that MRPL40 haploinsufficiency induced short-term potentiation abnormalities through mitochondrial-mediated deregulation of presynaptic Ca\(^{2+}\) levels, but did not lead to long-term plasticity or long-term memory [42]. The MRPS28 variants lead to intrauterine growth retardation, craniofacial dysmorphism and delayed development. In addition, the disease-causing variants in the MRPS28 were clarified [124]. A comprehensive analysis of major databases and literature showed that MRPS22 is one of the genes associated with the genetic etiology of primary ovarian insufficiency [74–76]. A few other key mitochondrial ribosomal genes have also been gradually elucidated. For example, MRPS30 is one of the potential gene loci for sporadic Parkinson’s disease in Chinese mainland Han population [125]; mrpl4 is one of the potential targets for the treatment of hypertension and stroke [126]; and MRPS25 mutation results in dyskinetic cerebral palsy and partial agenesis of the corpus callosum [127].

Mitochondrial related diseases caused by MRPs were present at all ages. The clinical characterization of diseases caused by the same MRP is not single and often synergistic with other proteins, making it difficult to identify the specific clinical characterization of MRP diseases. The functions of MRPs in regulating various mitochondrial diseases would be revealed gradually based on a large amount of studies in the future.

5.3. MRPs and Heart Diseases

As the main site of intracellular OXPHOS and ATP formation, mitochondria are important organelles that control and regulate metabolism. Abundant mitochondria with normal MRPs expression play crucial roles in maintaining the heart’s function. An abnormal MRPs expression causes heart disease including hypertrophic cardiomyopathy and blood clots, since MRPs are necessary for the mitochondrial respiratory chain complex to function properly.
A variant in \textit{MRPS14} caused perinatal hypertrophic cardiomyopathy with neonatal lactic acidosis, growth retardation, dysmorphia and neurological involvement. However, surprisingly, the mutant \textit{MRPS14} was stable and did not affect the assembly of the mt-SSU \cite{66}. \textit{MRPL44} associated with cardiomyopathy has reported that \textit{MRPL44} had mutation c.467T>G, (p.Leu156Arg) and c.233G>A, (p.Arg78Gln) in two unrelated patients with childhood hypertrophic cardiomyopathy. Similarly, the \textit{MRPL44} mutation was described in two Finnish siblings aged 6 months and 14 years, respectively. The presented hypertrophic cardiomyopathy, as a leading symptom, was accompanied by the heart tissue with respiratory complex I and complex IV deficiency and fibroblast separation complex IV deficiency \cite{128}. The \textit{MRPL44} mutation was one of the important causes of cardiomyopathy and it resulted in mitochondrial cardiomyopathy in human infants, which is based on the analysis of 66 myocardial cases in the Finnish heart transplant center \cite{45,46}. Moreover, the \textit{MRPL44} mutation not only resulted in this trait, but also caused hemiplegia migraine, pigmentary retinopathy and renal insufficiency Leigh-like lesions on brain MRI (magnetic resonance imaging) \cite{47}.

The mutation of \textit{MRPS22} is noticed to cause hypertrophic cardiomyopathy and fallopian tube lesions in a Turkish patient \cite{73}. However, there are also diverse findings, where a case reported a new homozygous splicing mutation in the \textit{MRPS22} gene c.339+5G>A in a patient with mild dysmorphism, hypotonia, and developmental delay. However, this patient did not develop hypertrophic cardiomyopathy and tubal disease \cite{129}. Pathogenic mutations in \textit{MRPL3} were responsible for the clinical phenotype of combined oxidative phosphorylation deficiency-9 (COXPD9), in which severe hypertrophic cardiomyopathy is a central presentation \cite{4}. \textit{mrpl16} has been shown to be significantly associated with septic cardiomyopathy \cite{17}. The genetic variation in \textit{MRPL37} was linked to an increased risk of venous thromboembolism recurrence \cite{37}. Meng et al. designed the cardiac hypertrophy cells by culturing the cardiac cells with 25 mmol/L D-glucose for 48 h. With the help of quantitative real-time PCR, it was confirmed that the expressions of \textit{mrpl50}, \textit{mrps2} and \textit{mrps21} were upregulated, and \textit{mrpl34} was downregulated \cite{33}. According to Bayesian multi-trait approaches and the Bayesian network analysis, \textit{MRPL38} was found to have significant effects on the cardiac traits such as left ventricular volume index, parasternal long axis interventricular septum thickness and mean left ventricular wall thickness \cite{130}.

5.4. MRPs Associated with Age and Other Related Mitochondrial Diseases

An abnormal MRPs expression was closely related with age. The specific downregulation of \textit{mrpl2} in the retina was identified in elderly APP/PS1 mice aged 8 months \cite{131}. The expression of \textit{mrpl4} decreased after a short period of fasting treatment and the methylation level of \textit{mrpl4} increased with age through the epigenetic map in mice \cite{105}. A single nucleotide polymorphism rs3209 in \textit{MRPL10} associated with early age-related macular degeneration (AMD) was also reported in Chinese Americans \cite{9}. However, other researchers have taken a different view, claiming they found no link between MRPs and longevity \cite{132}.

The association between abnormal MRPs expression and other diseases have been gradually confirmed. The DNA methylation of \textit{MRPS18-B} reduced survival in patients with tuberculosis and might be a determinant of long-term outcomes \cite{69}. \textit{MRPL44} is associated with a variety of asthma and allergy-related traits \cite{48}. \textit{MRPL3} is one of the recently discovered hub genes associated with acute mountain sickness, which may be used as a biomarker and therapeutic target for an accurate diagnosis and treatment in the future \cite{7}. \textit{MRPL36} is significantly associated with the meow syndrome by analyzing the protein interaction network \cite{36}. Moreover, MRPs can have a positive effect on the treatment of diseases. \textit{CRIF1} (MRPL64) can regulate the oxidative stress of irradiated bone marrow mesenchymal stem cells through phosphorylation of \textit{NRF2}^{Ser40}, which is helpful for the treatment of hemocytopenia, as well as multiple organ failures caused by hematopoietic dysfunction in the acute radiation syndrome \cite{56}. \textit{CRIF1} (MRPL64) interacting with CDK2 can enhance the radio-sensitivity of tumor cells \cite{133}. 
6. Conclusions and Perspectives

The development of a high-precision analysis technology of cryo-electron microscopy enables us to identify the structure of mitochondrial ribosomal proteins with a scale of 0.1 nm. Each of the 80 MRPs is essential for the mitochondrial ribosome composition, which plays an irreplaceable role in the assembly and translation of mitochondrial DNA. At present, studies of the relationship between MRPs and cell apoptosis are few. Although the apoptotic mechanisms of MRPS29, MRPL41 and MRPL65 have not been fully elucidated, they at least provide us with useful information to deeply study the apoptotic mechanisms of MRPs. We can further explore the changes of MRPs function or pathway-activating role in the process of inducing apoptosis, based on the analysis of the MRPs structure. Additionally, specific mechanisms can be clarified in the future.

The abnormal expression of MRPs and their encoding genes is closely associated with a variety of cancer and mitochondrial related diseases. Multiple MRPs are important predictors of disease diagnosis. However, the specific mechanisms of inducing the development of diseases is little known.

In the future, on the one hand, it is very important to strengthen the research on the relationship between the abnormal expression of MRPs, lack of their encoding genes, and diseases. On the other hand, some MRPs such as MRPS22, MRPL44 and MRPL28 that have been clarified as key factors in the development of cancer, which can be as biological targets to deeply study their specific pathways of influence, in order to lay a theoretical foundation for a targeted diagnosis and therapy of cancer in our research.

Author Contributions: Conceptualization, original draft preparation, writing—review and editing, G.H.; writing—review and editing, H.L. and H.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Key R&D Program of China (2018YFE0205100), the National Natural Science Foundation of China (11875061, 11505244), the National Natural Science Foundation of Gansu province (20JR5RA550), the National Laboratory of Heavy ion Accelerator of Lanzhou (E0HIRFL03P), and the Key Program of the National Natural Science Foundation of China (U1632270).

Acknowledgments: The authors would like to thank the anonymous reviewers who helped in improving the article by their valuable comments, as well as everyone who helped in the writing, submission, and revision process. The authors would also like to thank every fund that provided financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ban, N.; Beckmann, R.; Cate, J.H.; Dinman, J.D.; Dragon, F.; Ellis, S.R.; Lafontaine, D.L.; Lindahl, L.; Liljas, A.; Lipton, J.M.; et al. A new system for naming ribosomal proteins. *Curr. Opin. Struct. Biol.* 2014, 24, 165–169. [CrossRef] [PubMed]
2. Maki-Nevala, S.; Sarhadi, V.K.; Knuuttila, A.; Scheinin, I.; Ellonen, P.; Lagstrom, S.; Ronty, M.; Kettunen, E.; Husgafvel-Pursiainen, K.; Wolff, H.; et al. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing. *Lung* 2016, 194, 125–135. [CrossRef] [PubMed]
3. Cahill, L.S.; Cameron, J.M.; Winterburn, J.; Macos, P.; Hoggarth, J.; Dzamba, M.; Brudno, M.; Nutter, L.M.J.; Sproule, T.J.; Burgess, R.W.; et al. Structural Variant in Mitochondrial-Associated Gene (MRPL3) Induces Adult-Onset Neurodegeneration with Memory Impairment in the Mouse. *J. Neurosci.* 2020, 40, 4576–4585. [CrossRef] [PubMed]
4. Bursle, C.; Narendra, A.; Chuk, R.; Cardinal, J.; Justo, R.; Lewis, B.; Coman, D. COXPD9 an Evolving Multisystem Disease; Congenital Lactic Acidosis, Sensorineural Hearing Loss, Hypertrophic Cardiomyopathy, Cirrhosis and Interstitial Nephritis. *JIMD Rep.* 2017, 34, 105–109. [CrossRef] [PubMed]
5. Galmiche, L.; Serre, V.; Beinat, M.; Assouline, Z.; Lebre, A.S.; Chretien, D.; Nietschke, P.; Benes, V.; Boddart, N.; Sidi, D.; et al. Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. *Hum. Mutat.* 2011, 32, 1225–1231. [CrossRef] [PubMed]
6. Chen, K.; He, Y.; Liu, Y.; Yang, X. Gene signature associated with neuro-endocrine activity predicting prognosis of pancreatic carcinoma. *Mol. Genet. Genom. Med.* 2019, 7, e00729. [CrossRef]
7. Chang, Y.; He, J.; Tang, J.; Chen, K.; Wang, Z.; Xia, Q.; Li, H. Investigation of the gene co-expression network and hub genes associated with acute mountain sickness. *Hereditas* **2020**, *157*. [CrossRef]  
8. Morais-Rodrigues, F.; Silvério-Machado, R.; Kato, R.B.; Rodrigues, D.L.N.; Valdeze-Baex, J.; Fonseca, V.; San, E.J.; Gomes, L.G.R.; dos Santos, R.G.; Vinicius Canário, M.; et al. Analysis of the microarray gene expression for breast cancer progression after the application modified logistic regression. *Gene* **2020**, *726*. [CrossRef]  
9. Klein, R.; Li, X.; Kuo, J.Z.; Klein, B.E.; Cotch, M.F.; Wong, T.Y.; Taylor, K.D.; Rotter, J.I. Associations of candidate genes to age-related macular degeneration among racial/ethnic groups in the multi-ethnic study of atherosclerosis. *Am. J. Ophthalmol.* **2013**, *156*, 1010–1020.e1. [CrossRef]  
10. Besse, A.; Brezavar, D.; Hanson, J.; Larson, A.; Bonnen, P.E. LONP1 de novo dominant mutation causes mitochondrial encephalopathy with loss of LONP1 chaperone activity and excessive LONP1 proteolytic activity. *Mitochondrion* **2020**, *51*, 68–78. [CrossRef]  
11. Zhang, Q.; Liang, Z.; Gao, Y.; Teng, M.; Niu, L. Differentially expressed mitochondrial genes in breast cancer cells: Potential new targets for anti-cancer therapies. *Gene* **2017**, *596*, 45–52. [CrossRef] [PubMed]  
12. Yu, Y.; Guo, M.; Wei, Y.; Yu, S.; Li, H.; Wang, Y.; Xu, X.; Cui, Y.; Tian, J.; Liang, L.; et al. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. *Oncotarget* **2016**, *7*, 80888–80900. [CrossRef] [PubMed]  
13. Lee, Y.-K.; Lim, J.J.; Jeoun, U.-w.; Min, S.; Lee, E.-b.; Kwon, S.M.; Lee, C.; Yoon, G. Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. *J. Biol. Chem.* **2017**, *292*, 20208–20217. [CrossRef] [PubMed]  
14. Wang, K.; Li, L.; Fu, L.; Yuan, Y.; Dai, H.; Zhu, T.; Zhou, Y.; Yuan, F. Integrated Bioinformatics Analysis the Function of RNA Binding Proteins (RBPs) and Their Prognostic Value in Breast Cancer. *Front. Pharmacol.* **2019**, *10*, 140. [CrossRef] [PubMed]  
15. Xu, Y.H.; Deng, J.L.; Wang, L.P.; Zhang, H.B.; Tang, L.; Huang, Y.; Tang, J.; Wang, S.M.; Wang, G. Identification of Candidate Genes Associated with Breast Cancer Prognosis. *DNA Cell Biol.* **2020**, *39*, 1205–1227. [CrossRef]  
16. Sotgia, F.; Fiorillo, M.; Lisanti, M.P. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. *Oncotarget* **2017**, *8*, 68730–68745. [CrossRef] [PubMed]  
17. Kang, K.; Li, J.; Li, R.; Xu, X.; Liu, J.; Qin, L.; Huang, T.; Wu, J.; Jiao, M.; Wei, M.; et al. Potentially Critical Roles of NDUFB5, TIMMDC1, and VDAC3 in the Progression of Septic Cardiomyopathy Through Integrated Bioinformatics Analysis. *DNA Cell Biol.* **2020**, *39*, 105–117. [CrossRef]  
18. Zhang, L.; Huang, Y.; Ling, J.; Xiang, Y.; Zhuo, W. Screening of key genes and prediction of therapeutic agents in Arsenic-induced lung carcinoma. *Cancer Biomark.* **2019**, *25*, 351–360. [CrossRef]  
19. Ayakannu, T.; Taylor, A.H.; Konje, J.C. Selection of Endogenous Control Reference Genes for Studies on Type 1 or Type 2 Endometrial Cancer. *Sci. Rep.* **2020**, *10*, 8468. [CrossRef]  
20. Ayakannu, T.; Taylor, A.H.; Willets, J.M.; Brown, L.; Lambert, D.G.; McDonald, J.; Davies, Q.; Moss, E.L.; Konje, J.C. Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma. *Mol. Hum. Reprod.* **2015**, *21*, 723–735. [CrossRef]  
21. Wu, D.; Zhao, J.; Ma, H.; Wang, M.C. Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin’s lymphoma. *Cancer Genet* **2020**, *243*, 7–10. [CrossRef] [PubMed]  
22. Christensen, J.N.; Schmidt, H.; Steiniche, T.; Madsen, M. Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines. *Melanoma Res.* **2020**, *30*, 26–38. [CrossRef]  
23. Aasebø, E.; Berven, F.S.; Hovland, R.; Døskeland, S.O.; Bruserud, Ø.; Selheim, F.; Hernandez-Valladares, M. The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. *Cancers* **2020**, *12*, 1466. [CrossRef] [PubMed]  
24. Yuan, Z.; Yu, Y.; Zhang, B.; Miao, L.; Wang, L.; Zhao, K.; Ji, Y.; Wang, R.; Ma, H.; Chen, N.; et al. Genetic variants in lncRNA H19 are associated with the risk of squamous cell carcinoma in a Chinese population. *Oncotarget* **2018**, *9*, 23915–23922. [CrossRef] [PubMed]  
25. Tang, N.Y.; Chuhe, F.S.; Yu, C.C.; Liao, C.L.; Lin, J.J.; Hsia, T.C.; Wu, K.C.; Liu, H.C.; Lu, K.W.; Chung, J.G. Benzyl isothiocyanate alters the gene expression with cell cycle regulation and cell death in human brain glioblastoma GBM 8401 cells. *Oncol. Rep.* **2016**, *35*, 2089–2096. [CrossRef]
26. Di Nottia, M.; Marchese, M.; Verriigni, D.; Mutti, C.D.; Torraco, A.; Oliva, R.; Fernandez-Vizarra, E.; Morani, F.; Trani, G.; Rizza, T.; et al. A homozygous MRPL24 mutation causes a complex movement disorder and affects the mitoribosome assembly. *Neurobiol. Dis.* 2020, 141. [CrossRef]

27. Sotgia, F.; Lisanti, M.P. Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine. *Oncotarget* 2017, 8, 67117–67128. [CrossRef]

28. Qiu, R.; Shi, H.; Wang, S.; Leng, S.; Liu, R.; Zheng, Y.; Huang, W.; Zeng, Y.; Gao, J.; Zhang, K.; et al. BRMS1 coordinates with LSD1 and suppresses breast cancer cell metastasis. *Am. J. Cancer Res.* 2018, 8, 2030–2045.

29. Liu, L.; Luo, C.; Luo, Y.; Chen, L.; Liu, Y.; Wang, Y.; Han, J.; Zhang, Y.; Wei, N.; Xie, Z.; et al. MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression. *Oncogene* 2018, 37, 86–94. [CrossRef]

30. Li, J.; Feng, D.; Gao, C.; Zhang, Y.; Xu, J.; Wu, M.; Zhan, X. Isoforms S and L of MRPL33 from alternative splicing have isoform-specific roles in the cheemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway. *Int. J. Oncol.* 2019. [CrossRef]

31. Lebedev, T.D.; Vagapova, E.R.; Popenko, V.I.; Leonova, O.G.; Spirin, P.V.; Prassolov, V.S. Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia. *Front. Oncol.* 2019, 9, 1046. [CrossRef] [PubMed]

32. Guo, T.; Zambo, K.D.A.; Zamuner, F.T.; Ou, T.; Hopkins, C.; Kelley, D.Z.; Wulf, H.A.; Winkler, E.; Erbe, R.; Danilova, L.; et al. Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. *Epigenetics* 2020, 1–13. [CrossRef] [PubMed]

33. Meng, Z.; Chen, C.; Cao, H.; Wang, J.; Shen, E. Whole transcriptome sequencing reveals biologically significant RNA markers and related regulating biological pathways in cardiomyocyte hypertrophy induced by high glucose. *J. Cell. Biochem.* 2019, 120, 1018–1027. [CrossRef] [PubMed]

34. Alshabi, A.M.; Vastrad, B.; Shaikh, I.A.; Vastrad, C. Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiforme by Bioinformatics Analysis. *Biomolecules* 2019, 9, 201. [CrossRef] [PubMed]

35. Zhang, L.; Lu, P.; Yan, L.; Yang, L.; Wang, Y.; Chen, J.; Dai, J.; Li, Y.; Kang, Z.; Bai, T.; et al. MRPL35 is Up-Regulated in Colorectal Cancer and Regulates Colorectal Cancer Cell Growth and Apoptosis. *Am. J. Pathol.* 2019, 189, 1105–1120. [CrossRef]

36. Corrêa, T.; Feltes, B.C.; Riegel, M. Integrated analysis of the critical region 5p15.3–p15.2 associated with cri-du-chat syndrome. *Genet. Mol. Biol.* 2019, 42 (Suppl. 1), 186–196. [CrossRef]

37. Sundquist, K.; Ahmad, A.; Svensson, P.J.; Zoller, B.; Sundquist, J.; Memon, A.A. Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner. *J. Thromb. Thrombolysis* 2018, 46, 154–165. [CrossRef]

38. Sultana, N.; Rahman, M.; Myti, S.; Islam, J.; Mustafa, M.G.; Nag, K. A novel knowledge-derived data potentiizing method revealed unique liver cancer-associated genetic variants. *Hum. Genom.* 2019, 13. [CrossRef]

39. Yu, M.J.; Zhao, N.; Shen, H.; Wang, H. Long Noncoding RNA MRPL39 Inhibits Gastric Cancer Proliferation and Progression by Directly Targeting miR-130. *Genet. Test. Mol. Biomark.* 2018, 22, 656–663. [CrossRef]

40. Napoli, E.; Tassone, F.; Wong, S.; Angkustsiri, K.; Simon, T.J.; Song, G.; Giuliani, C. Mitochondrial Citrate Transporter-dependent Metabolic Signature in the 22q11.2 Deletion Syndrome. *J. Biol. Chem.* 2015, 290, 23240–23253. [CrossRef]

41. Li, J.; Ryan, S.K.; Deboer, E.; Cook, K.; Fitzgerald, S.; Lachman, H.M.; Wallace, D.C.; Goldberg, E.M.; Anderson, S.A. Mitochondrial deficits in human iPSC-derived neurons from patients with 22q11.2 deletion syndrome and schizophrenia. *Transl. Psychiatry* 2019, 9, 302. [CrossRef]

42. Devaraju, P.; Yu, J.; Eddins, D.; Mellado-Lagarde, M.M.; Earls, L.R.; Westmoreland, J.J.; Quarato, G.; Green, D.R.; Zakharenko, S.S. Haploinsufficiency of the 22q11.2 microdeletion gene Mrpl40 disrupts short-term synaptic plasticity and working memory through dysregulation of mitochondrial calcium. *Mol. Psychiatry* 2016, 22, 1313–1326. [CrossRef] [PubMed]

43. Hao, C.; Duan, H.; Li, H.; Wang, H.; Liu, Y.; Fan, Y.; Zhang, C. Knockdown of MRPL42 suppresses glioma cell proliferation by inducing cell cycle arrest and apoptosis. *Biosci. Rep.* 2018, 38. [CrossRef] [PubMed]

44. Wu, S.; Yuan, W.; Shen, Y.; Lu, X.; Li, Y.; Tian, L.; Jiang, L.; Zhuang, X.; Wu, J.; Chu, M. The miR-608 rs4919510 polymorphism may modify cancer susceptibility based on type. *Tumour Biol.* 2017, 39. [CrossRef] [PubMed]

45. Vasilescu, C.; Ojala, T.H.; Brilliante, V.; Ojanen, S.; Hinterding, H.M.; Palin, E.; Alastalo, T.P.; Koskenvuo, J.; Hiippala, A.; Jokinen, E.; et al. Genetic Basis of Severe Childhood-Onset Cardiomyopathies. *J. Am. Coll. Cardiol.* 2018, 72, 2324–2338. [CrossRef] [PubMed]
46. Yeo, J.H.; Skinner, J.P.; Bird, M.J.; Formosa, L.E.; Zhang, J.G.; Kluck, R.M.; Belz, G.T.; Chong, M.M. A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity. *PloS ONE* **2015**, *10*, e0134326. [CrossRef]

47. Distelmaier, F.; Haack, T.B.; Catarino, C.B.; Gallenmüller, C.; Rodenberg, R.J.; Strom, T.M.; Baertling, F.; Meitinger, T.; Mayatepek, E.; Proksch, H.; et al. MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy. *Neurogenetics* **2015**, *16*, 319–323. [CrossRef]

48. Morin, A.; Madore, A.M.; Kwan, T.; Ban, M.; Partanen, J.; Rönöblom, L.; Syvänen, A.C.; Sawcer, S.; Stunnenberg, H.; Lathrop, M.; et al. Exploring rare and low-frequency variants in the Saguenay-Lac-Saint-Jean population identified genes associated with asthma and allergy traits. *Eur. J. Hum. Genet. EJHG* **2019**, *27*, 90–101. [CrossRef]

49. Antony, F.; Deantonio, C.; Cotella, D.; Soluri, M.F.; Tarasiuk, O.; Raspagliesi, F.; Adorni, F.; Piazza, S.; Ciani, Y.; Santoro, C.; et al. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. *OncolImmunology* **2019**, *8*. [CrossRef]

50. Abaji, R.; Ceppi, F.; Patel, S.; Gagné, V.; Xu, C.J.; Spinella, J.F.; Colombini, A.; Parasole, R.; Buldini, B.; Basso, G.; et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. *Pharmacogenomics* **2018**, *19*, 1181–1193. [CrossRef]

51. Maiuthed, A.; Prakhongcheep, O.; Chanvorachote, P. Microarray-based Analysis of Genes, Transcription Factors, and Epigenetic Modifications in Lung Cancer Exposed to Nitric Oxide. *Cancer Genom. Proteom.* **2020**, *17*, 401–415. [CrossRef] [PubMed]

52. Abdul Aziz, N.A.; Mokhtar, N.M.; Harun, R.; Mollah, M.M.; Mohamed Rose, I.; Sagap, I.; Mohd Tamil, A.; Wan Ngah, W.Z.; Jamal, R. A 19-Gene expression signature as a predictor of survival in colorectal cancer. *BMC Med. Genom.* **2016**, *9*, 58. [CrossRef] [PubMed]

53. López-Cortés, A.; Cabrera-Andrade, A.; Vázquez-Naya, J.M.; Pazos, A.; Gonzáles-Díaz, H.; Paz, Y.M.C.; Guerrero, S.; Pérez-Castillo, Y.; Tejera, E.; Munteanu, C.R. Prediction of breast cancer proteins involved in immunotherapy, metastasis, and RNA-binding using molecular descriptors and artificial neural networks. *Sci. Rep.* **2020**, *10*, 8515. [CrossRef] [PubMed]

54. Zhuang, R.; Lu, D.; Zhuo, J.; Zhang, X.; Wang, K.; Wei, X.; Wei, Q.; Wang, W.; Xie, H.; Zhou, L.; et al. CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. *Oncotarget* **2017**, *8*, 94759–94768. [CrossRef] [PubMed]

55. Váhedi, S.; Chueh, F.Y.; Chandran, B.; Yu, C.L. Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation. *BMC Cancer* **2015**, *15*, 551. [CrossRef] [PubMed]

56. Chen, L.; Ran, Q.; Xiang, Y.; Xiang, L.; Chen, L.; Li, F.; Wu, J.; Wu, C.; Li, Z. Co-Activation of PKC-δ by CRIF1 Modulates Oxidative Stress in Bone Marrow Multipotent Mesenchymal Stromal Cells after Irradiation by Phosphorylating NFR2 Ser40. *Theranostics* **2017**, *7*, 2634–2648. [CrossRef] [PubMed]

57. Ramchandran, R.; Piao, S.; Lee, J.W.; Nagar, H.; Jung, S.-b.; Choi, S.; Kim, S.; Lee, I.; Kim, S.-m.; Shin, N.; et al. CR6-interacting factor 1 deficiency promotes endothelial inflammation by SIRT1 downregulation. *PloS ONE* **2018**, *13*, e0192693. [CrossRef]

58. Nagar, H.; Jung, S.B.; Ryu, M.J.; Choi, S.J.; Piao, S.; Song, H.J.; Kang, S.K.; Shin, N.; Kim, D.W.; Jin, S.A.; et al. CR6-Interacting Factor 1 Deficiency Impairs Vascular Function by Inhibiting the Sirt1-Endothelial Nitric Oxide Synthase Pathway. *Antioxid. Redox Signal.* **2017**, *27*, 234–249. [CrossRef]

59. Park, J.S.; Choi, S.Y.; Hwang, S.H.; Kim, S.M.; Choi, J.; Jung, K.A.; Kwon, J.Y.; Kong, Y.Y.; Cho, M.L.; Park, S.H. CR6-interacting factor 1 controls autoimmune arthritis by regulation of signal transducer and activator of transcription 3 pathway and T helper type 17 cells. *Immunochemistry* **2019**, *156*, 413–421. [CrossRef]

60. Zhou, C.; Chen, Z.; Peng, C.; Chen, C.; Li, H. Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A. *Cancer Biother. Radiopharm.* **2020**. [CrossRef]

61. Tian, A.; Pu, K.; Li, B.; Li, M.; Liu, X.; Gao, L.; Mao, X. Weighted gene coexpression network analysis reveals hub genes involved in cholangiocarcinoma progression and prognosis. *Hepatol. Res. 2019*, *49*, 1195–1206. [CrossRef] [PubMed]

62. Akbergenov, R.; Duscha, S.; Fritz, A.K.; Juskeviciene, R.; Oishi, N.; Schmitt, K.; Scherbakov, D.; Teo, Y.; Boukari, H.; Freihofer, P.; et al. Mutant MRPS5 affects mitoribosomal accuracy and confers stress-related behavioral alterations. *EMBO Rep.* **2018**, *19*. [CrossRef] [PubMed]
63. Liu, J.; Wu, S.; Xie, X.; Wang, Z.; Lei, Q. Identification of potential crucial genes and key pathways in osteosarcoma. *Hereditas* 2020, 157. [CrossRef] [PubMed]

64. Menezes, M.J.; Guo, Y.; Zhang, J.; Riley, L.G.; Cooper, S.T.; Thorburn, D.R.; Li, J.; Dong, D.; Li, Z.; Glessner, J.; et al. Mutation in mitochondrial ribosomal protein S7 (MRPS7) causes congenital sensorineural deafness, progressive hepatic and renal failure and lactic acidemia. *Hum. Mol. Genet.* 2015, 24, 2297–2307. [CrossRef]

65. Zhao, D.D.; Zhao, X.; Li, W.T. Identification of differentially expressed metastatic genes and their signatures to predict the overall survival of uveal melanoma patients by bioinformatics analysis. *Int. J. Ophthalmol.* 2020, 13, 1046–1053. [CrossRef]

66. Jackson, C.B.; Huemer, M.; Bolognini, R.; Martin, F.; Szinnai, G.; Donner, B.C.; Richter, U.; Battersby, B.J.; Nuoffer, J.M.; Suomalainen, A.; et al. A variant in MRPS14 (uS14m) causes perinatal hypertrophic cardiomyopathy with neonatal lactic acidosis, growth retardation, dysmorphic features and neurological involvement. *Hum. Mol. Genet.* 2019, 28, 639–649. [CrossRef]

67. Mushtaq, M.; Jensen, L.; Davidsson, S.; Grygoruk, O.V.; Andren, O.; Kashuba, V.; Kashuba, E. The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells. *Sci. Rep.* 2018, 8, 2268. [CrossRef]

68. Mushtaq, M.; Ali, R.H.; Kashuba, V.; Klein, G.; Kashuba, E. S18 family of mitochondrial ribosomal proteins: Evolutionary history and Gly132 polymorphism in colon carcinoma. *Oncotarget* 2016, 7, 55649–55662. [CrossRef]

69. Chen, Y.C.; Hsiao, C.C.; Chen, T.W.; Wu, C.C.; Chao, T.Y.; Leung, S.Y.; Eng, H.L.; Lee, C.P.; Wang, T.Y.; Lin, M.C. Whole Genome DNA Methylation Analysis of Active Pulmonary Tuberculosis Disease Identifies Novel Epigenotypes: PARP9/miR-505/RASGRP4/GNG12 Gene Methylation and Clinical Phenotypes. *Int. J. Mol. Sci.* 2020, 21, 3180. [CrossRef]

70. Hamdi, Y.; Soucy, P.; Adoue, V.; Michailidou, K.; Canisius, S.; Lemaçon, A.; Droit, A.; Andrulis, I.L.; Anton-Culver, H.; Arndt, V.; et al. Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget* 2016, 7, 80140–80163. [CrossRef]

71. Rodríguez-García, M.E.; Cotrina-Vinagre, F.J.; Carnicer-Rodríguez, P.; Martínez-Azorín, F. An innovative strategy to clone positive modifier genes of defects caused by mtDNA mutations: MRPS18C as suppressor gene of m.3946G > A mutation in MT-ND1 gene. *Hum. Genet.* 2017, 136, 885–896. [CrossRef] [PubMed]

72. Bertini, V.; Valetto, A.; Baldinotti, F.; Azzara, A.; Cambi, F.; Toschi, B.; Giacomina, A.; Gatti, G.L.; Gana, S.; Caligo, M.A.; et al. Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome: New Report with a 197-kb deletion upstream of FOXL2 and Review of the Literature. *Mol. Syndromol.* 2019, 10, 147–153. [CrossRef] [PubMed]

73. Baertling, F.; Haack, T.B.; Rodenburg, R.J.; Schaper, J.; Seibt, A.; Strom, T.M.; Meitinger, T.; Mayatepek, E.; Hadzik, B.; Selcan, G.; et al. MRPS22 mutation causes fatal neonatal lactic acidosis with brain and heart abnormalities. *Neurogenetics* 2015, 16, 237–240. [CrossRef] [PubMed]

74. Chen, A.; Tiosano, D.; Gurun, T.; Baris, H.N.; Bayram, Y.; Mory, A.; Shapiro-Kulnane, L.; Hodges, C.A.; Akdemir, Z.C.; Turan, S.; et al. Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency. *Hum. Mol. Genet.* 2018, 27, 1913–1926. [CrossRef] [PubMed]

75. Franca, M.M.; Mendonca, B.B. Genetics of Primary Ovarian Insufficiency in the Next-Generation Sequencing Era. *J. Endocr. Soc.* 2020, 4, bvz037. [CrossRef] [PubMed]

76. Tiosano, D.; Mears, J.A.; Buchner, D.A. Mitochondrial Dysfunction in Primary Ovarian Insufficiency. *Endocrinology* 2019, 160, 2353–2367. [CrossRef]

77. Pu, M.; Wang, J.; Huang, Q.; Zhao, G.; Xia, C.; Shang, R.; Zhang, Z.; Bian, Z.; Yang, X.; Tao, K. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. *Tumour Biol.* 2017, 39. [CrossRef]

78. Borna, N.N.; Kishita, Y.; Kohda, M.; Lim, S.C.; Shimura, M.; Wu, Y.; Mogushi, K.; Yatsuka, Y.; Harashima, H.; Hisatomi, Y.; et al. Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome. *Neurogenetics* 2019, 20, 9–25. [CrossRef]

79. Amunts, A.; Brown, A.; Toots, J.; Scheres, S.H.W.; Ramakrishnan, V. Ribosome. The structure of the human mitochondrial ribosome. *Science* 2015, 348, 95–98. [CrossRef]

80. Yusupov, M.M.; Yusupova, G.Z.; Baucom, A.; Lieberman, K.; Earnest, T.N.; Cate, J.H.; Noller, H.F. Crystal structure of the ribosome at 5.5 Å resolution. *Science* 2001, 292, 883–896. [CrossRef]
Gray, M.W.; Burger, G.; Lang, B.F. The origin and early evolution of mitochondria. *Genome Biol.* 2001, 2, Reviews1018. [CrossRef] [PubMed]

Sharma, M.R.; Koc, E.C.; Datta, P.P.; Booth, T.M.; Spremulli, L.L.; Agrawal, R.K. Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. *Cell* 2003, 115, 97–108. [CrossRef]

Kaushal, P.S.; Sharma, M.R.; Booth, T.M.; Haque, E.M.; Tung, C.S.; Sanbonmatsu, K.Y.; Spremulli, L.L.; Agrawal, R.K. Cryo-EM structure of the small subunit of the mammalian mitochondrial ribosome. *Proc. Natl. Acad. Sci. U.S.A.* 2014, 111, 7284–7289. [CrossRef] [PubMed]

Greber, B.J.; Boehringer, D.; Leibundgut, M.; Bieri, P.; Leitner, A.; Schmitz, N.; Aebersold, R.; Ban, N. The complete structure of the large subunit of the mammalian mitochondrial ribosome. *Nature* 2014, 515, 283–286. [CrossRef] [PubMed]

Greber, B.J.; Bieri, P.; Leibundgut, M.; Leitner, A.; Aebersold, R.; Boehringer, D.; Ban, N. Ribosome. The complete structure of the 55S mammalian mitochondrial ribosome. *Science* 2015, 348, 303–308. [CrossRef]

Brown, A.; Amunts, A.; Bai, X.C.; Sugimoto, Y.; Edwards, P.C.; Murshudov, G.; Scheres, S.H.W.; Ramakrishnan, V. Structure of the large ribosomal subunit from human mitochondria. *Science* 2014, 346, 718–722. [CrossRef]

Davies, S.M.; Rachkan, O.; Shearwood, A.M.; Hamilton, K.L.; Narasi, R.; Whelan, J.; Filipovska, A. Pentatricopeptide repeat domain protein 3 associates with the mitochondrial small subunit and regulates translation. *FEBS Lett.* 2009, 583, 1853–1858. [CrossRef]

Rabl, J.; Leibundgut, M.; Ataide, S.F.; Haag, A.; Ban, N. Crystal structure of the eukaryotic 40S ribosomal subunit in complex with initiation factor 1. *Science* 2011, 331, 730–736. [CrossRef]

Kim, H.R.; Chae, H.J.; Thomas, M.; Miyazaki, T.; Monosov, A.; Monosov, E.; Krajewksa, M.; Krajewski, S.; Reed, J.C. Mammalian dap3 is an essential gene required for mitochondrial homeostasis in vivo and contributing to the extrinsic pathway for apoptosis. *FASEB J.* 2007, 21, 188–196. [CrossRef]

Davies, K.M.; Anselmi, C.; Witting, I.; Faraldo-Gomez, J.D.; Kuhlbrandt, W. Structure of the yeast FiFo-ATP synthase dimer and its role in shaping the mitochondrial cristae. *Proc. Natl. Acad. Sci. USA* 2012, 109, 13602–13607. [CrossRef]

Gopisetty, G.; Thangarajan, R. Mammalian mitochondrial ribosomal small subunit (MRPS) genes: A putative role in human disease. *Gene* 2016, 589, 27–35. [CrossRef] [PubMed]

Cavdar Koc, E.; Ranasinghe, A.; Burkhart, W.; Blackburn, K.; Koc, H.; Moseley, A.; Spremulli, L.L. A new face on apoptosis: Death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. *FEBS Lett.* 2001, 492, 166–170. [CrossRef] [PubMed]

Gilkerson, R.W.; Margineantu, D.H.; Capaldi, R.A.; Selker, J.M. Mitochondrial DNA depletion causes morphological changes in the mitochondrial reticulum of cultured human cells. *FEBS Lett.* 2000, 474, 1–4. [CrossRef]

Miyazaki, T.; Shen, M.; Fujikura, D.; Tosa, N.; Kim, H.R.; Kon, S.; Uede, T.; Reed, J.C. Functional role of death-associated protein 3 (DAP3) in anoikis. *J. Biol. Chem.* 2004, 279, 44667–44672. [CrossRef] [PubMed]

Cohen, O.; Inbal, B.; Kissil, J.L.; Raveh, T.; Berissi, H.; Spivak-Kroizaman, T.; Feinstein, E.; Kimchi, A. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. *J. Cell Biol.* 1999, 146, 141–148. [CrossRef]

Mukamel, Z.; Kimchi, A. Death-associated protein 3 localizes to the mitochondria and is involved in the process of mitochondrial fragmentation during cell death. *J. Biol. Chem.* 2004, 279, 36732–36738. [CrossRef]

Miyazaki, T.; Reed, J.C. A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. *Nat. Immunol.* 2001, 2, 493–500. [CrossRef]

Berger, T.; Kretzler, M. Interaction of DAP3 and FADD only after cellular disruption. *Nat. Immunol.* 2002, 3, 3–5. [CrossRef]

Wazir, U.; Orakzai, M.M.; Khanzada, Z.S.; Jiang, W.G.; Sharma, A.K.; Kasem, A.; Mokbel, K. The role of death-associated protein 3 in apoptosis, anoikis and human cancer. *Cancer Cell Int.* 2015, 15, 39. [CrossRef]

Chintharlapalli, S.R.; Jasti, M.; Malladi, S.; Parsa, K.V.; Ballester, R.P.; Gonzalez-Garcia, M. BMRP is a Bcl-2 binding protein that induces apoptosis. *J. Cell. Biochem.* 2005, 94, 611–626. [CrossRef]

Malladi, S.; Parsa, K.V.; Bhupathi, D.; Rodriguez-Gonzalez, M.A.; Conde, J.A.; Anumula, P.; Romo, H.E.; Claunch, C.J.; Ballester, R.P.; Gonzalez-Garcia, M. Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2. *Mol. Cell. Biochem.* 2011, 351, 217–232. [CrossRef] [PubMed]
117. Lake, N.J.; Webb, B.D.; Stroud, D.A.; Richman, T.R.; Ruzzenente, B.; Compton, A.G.; Mountford, H.S.;
111. Yan, H.X.; Zhang, Y.J.; Zhang, Y.; Ren, X.; Shen, Y.F.; Cheng, M.B.; Zhang, Y. CRIF1 enhances p53 activity via
109. Wu, B.; Pan, Y.; Liu, G.; Yang, T.; Jin, Y.; Zhou, F.; Wei, Y. MRPS30-DT Knockdown Inhibits Breast Cancer
102. Yoo, Y.A.; Kim, M.J.; Park, J.K.; Chung, Y.M.; Lee, J.H.; Chi, S.G.; Kim, J.S.; Yoo, Y.D. Mitochondrial ribosomal
119. Chung, H.K.; Ryu, D.; Kim, K.S.; Chang, J.Y.; Kim, Y.K.; Yi, H.S.; Kang, S.G.; Choi, M.J.; Lee, S.E.; Jung, S.B.; et al.
114. Gao, H.Y.; Wang, W.; Luo, X.G.; Jiang, Y.F.; He, X.; Xu, P.; Chen, X.; Li, X.Y. Screening of prognostic risk
113. Wang, Z.; Li, J.; Long, X.; Jiao, L.; Zhou, M.; Wu, K. MRPS16 facilitates tumor progression via the
112. Ye, J.; Li, H.; Wei, J.; Luo, Y.; Liu, H.; Zhang, J.; Luo, Y. Risk Scoring System based on lncRNA Expression
106. Ghoussaini, M.; French, J.D.; Michailidou, K.; Nord, S.; Beesley, J.; Canisus, S.; Hillman, K.M.; Kaufmann, S.;
104. Sun, L.; Liu, Y.; Fr
103. Kim, M.J.; Yoo, Y.A.; Kim, H.J.; Kang, S.; Kim, Y.G.; Kim, J.S.; Yoo, Y.D. Mitochondrial ribosomal protein L41
118. Shin, J.M.; Choi, D.K.; Sohn, K.C.; Kim, J.Y.; Im, M.; Lee, Y.; Soo, Y.J.; Shong, M.; Lee, J.H.; Kim, C.D. Targeted
deletion of Crif1 in mouse epidermis impairs skin homeostasis and hair morphogenesis. Sci. Rep. 2017, 7, 44828. [CrossRef]
110. Chen, C.W.; Fu, M.; Du, Z.H.; Zhao, F.; Yang, W.W.; Xu, L.H.; Li, S.L.; Ge, X.Y. Long Noncoding RNA
108. Guo, X.; Lin, W.; Bao, J.; Cai, Q.; Pan, X.; Bai, M.; Yuan, Y.; Shi, J.; Sun, Y.; Han, M.R.; et al. A Comprehensive
cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide
Association Studies. Am. J. Hum. Genet. 2018, 102, 890–903. [CrossRef]
109. Wu, B.; Pan, Y.; Liu, G.; Yang, T.; Jin, Y.; Zhou, F.; Wei, Y. MRPS30-DT Knockdown Inhibits Breast Cancer
Progression by Targeting Jab1/Cops5. Front. Oncol. 2019, 9, 1170. [CrossRef]
111. Yan, H.X.; Zhang, Y.J.; Zhang, Y.; Ren, X.; Shen, Y.F.; Cheng, M.B.; Zhang, Y. CRIF1 enhances p53 activity via
the chromatin remodeler SNF5 in the HCT116 colon cancer cell lines. Biochim. Biophys. Acta Gene Regul.
Mech. 2017, 1860, 516–522. [CrossRef] [PubMed]
112. Ye, J.; Li, H.; Wei, J.; Luo, Y.; Liu, H.; Zhang, J.; Luo, X. Risk Scoring System based on lncRNA Expression
for Predicting Survival in Hepatocellular Carcinoma with Cirrhosis. Asian Pac. J. Cancer Prev. 2020, 21, 1787–1795. [CrossRef] [PubMed]
113. Wang, Z.; Li, J.; Long, X.; Jiao, L.; Zhou, M.; Wu, K. MRPS16 facilitates tumor progression via the
PI3K/AKT/Snail signaling axis. J. Cancer 2020, 11, 2032–2043. [CrossRef] [PubMed]
114. Gao, H.Y.; Wang, W.; Luo, X.G.; Jiang, Y.F.; He, X.; Xu, P.; Chen, X.; Li, X.Y. Screening of prognostic risk
microRNAs for acute myeloid leukemia. Hematology 2018, 23, 747–755. [CrossRef]
115. Li, H.B.; Wang, R.X.; Jiang, H.B.; Zhang, E.D.; Tan, J.Q.; Xu, H.Z.; Zhou, R.R.; Xia, X.B. Mitochondrial
Ribosomal Protein L10 Associates with Cyclin B1 and AKT. DNA Cell Biol. 2016, 35, 680–690. [CrossRef]
116. Barsh, G.S.; Kohda, M.; Tokuzawa, Y.; Kishita, Y.; Nyuzuki, H.; Moriyma, Y.; Mizuno, Y.; Hirata, T.;
Yatsuka, Y.; Yamashita-Sugahara, Y.; et al. A Comprehensive Genomic Analysis Reveals the Genetic
Landscape of Mitochondrial Respiratory Chain Complex Deficiencies. PLoS Genet. 2016, 12. [CrossRef]
117. Lake, N.J.; Webb, B.D.; Stroud, D.A.; Richman, T.R.; Ruzzeneente, B.; Compton, A.G.; Mountford, H.S.;
Pullman, J.; Zangarelli, C.; Rio, M.; et al. Biallelic Mutations in MRPS34 Lead to Instability of the Small
Mitoribosomal Subunit and Leigh Syndrome. Am. J. Hum. Genet. 2017, 101, 239–254. [CrossRef]
118. Shin, J.M.; Choi, D.K.; Sohn, K.C.; Kim, J.Y.; Im, M.; Lee, Y.; Seo, Y.J.; Shong, M.; Lee, J.H.; Kim, C.D. Targeted
deletion of Crif1 in mouse epidermis impairs skin homeostasis and hair morphogenesis. Sci. Rep. 2017, 7, 44828. [CrossRef]
119. Chung, H.K.; Ryu, D.; Kim, K.S.; Chang, J.Y.; Kim, Y.K.; Yi, H.S.; Kang, S.G.; Choi, M.J.; Lee, S.E.; Jung, S.B.; et al.
Growth differentiation factor 15 is a myomitoine governing systemic energy homeostasis. J. Cell Biol. 2017, 216, 149–165. [CrossRef]
120. Jung, S.-B.; Choi, M.J.; Ryu, D.; Yi, H.-S.; Lee, S.E.; Chang, J.Y.; Chung, H.K.; Kim, Y.K.; Kang, S.G.; Lee, J.H.; et al. Reduced oxidative capacity in macrophages results in systemic insulin resistance. *Nat. Commun.* 2018, 9. [CrossRef]

121. Hunter, C.A.; Kartal, F.; Koc, Z.C.; Murphy, T.; Kim, J.H.; Dervir, J.; Koc, E.C. Mitochondrial oxidative phosphorylation is impaired in TALLYHO mice, a new obesity and type 2 diabetes animal model. *Int. J. Biochem. Cell Biol.* 2019, 116, 105616. [CrossRef] [PubMed]

122. Zheng, N.; Wei, D.; Dai, B.; Zheng, L.; Zhao, M.; Xin, N.; Chi, Z.; Zhao, Y.; Ma, T.; Jahane, R.; et al. Mitochondrial Genome Encoded Proteins Expression Disorder, the Possible Mechanism of the Heart Disease in Metabolic Syndrome. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* 2017, 43, 959–968. [CrossRef] [PubMed]

123. Gardeitchik, T.; Mohamed, M.; Ruzzenente, B.; Karall, D.; Guerrero-Castillo, S.; Dalloyaux, D.; van den Brand, M.; van Kraaij, S.; van Asbeck, E.; Assouline, Z.; et al. Bi-allelic Mutations in the Mitochondrial Ribosomal Protein MRPS2 Cause Sensorineural Hearing Loss, Hypoglycemia, and Multiple OXPHOS Complex Deficiencies. *Am. J. Hum. Genet.* 2018, 102, 685–695. [CrossRef] [PubMed]

124. Pulman, J.; Ruzzenente, B.; Bianchi, L.; Rio, M.; Boddaert, N.; Munnich, A.; Röting, A.; Metodiev, M.D. Mutations in the MRPS28 gene encoding the small mitoribosomal subunit protein bS1m in a patient with intrauterine growth retardation, craniofacial dysmorphism and multisystemic involvement. *Hum. Mol. Genet.* 2019, 28, 1445–1462. [CrossRef]

125. Hu, Y.; Deng, L.; Zhang, J.; Fang, X.; Mei, P.; Cao, X.; Lin, J.; Wei, Y.; Zhang, X.; Xu, R. A Pooling Genome-Wide Association Study Combining a Pathway Analysis for Typical Sporadic Parkinson’s Disease in the Han Population of Chinese Mainland. *Mol. Neurobiol.* 2016, 53, 4302–4318. [CrossRef]

126. Zhao, Q.; Sun, H.; Yin, L.; Wang, L. miR-126a-5p-Dbp and miR-31a-Crot/Mrpl4 interaction pairs crucial for the development of hypertension and stroke. *Mol. Med. Rep.* 2019, 20, 4151–4167. [CrossRef]

127. Bugiardini, E.; Mitchell, A.L.; Rosa, I.D.; Horning-Do, H.T.; Pitmann, A.M.; Poole, O.V.; Holton, J.L.; Shah, S.; Woodward, C.; Hargreaves, I.; et al. MRPS25 mutations impair mitochondrial translation and cause encephalomyopathy. *Hum. Mol. Genet.* 2019, 28, 1445–1462. [CrossRef]

128. Carroll, C.J.; Isohanni, P.; Poyhonen, R.; Euro, L.; Richter, U.; Brillante, V.; Gotz, A.; Lahtinen, T.; Paetau, A.; Pihko, H.; et al. Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy. *J. Med. Genet.* 2013, 50, 151–159. [CrossRef]

129. Kılıç, M.; Oğuz, K.K.; Kılıç, E.; Yüksel, D.; Demirci, H.; Sağroğlu, M.; Yücel-Yılmaz, D.; Özsül, R.K. A patient with mitochondrial disorder due to a novel mutation in MRPS22. *Metab. Brain Dis.* 2017, 32, 1389–1393. [CrossRef]

130. Yazdani, A.; Yazdani, A.; Méndez Giráldez, R.; Aguilar, D.; Sartore, L. A Multi-Trait Approach Identified Genetic Variants Including a Rare Mutation in RGS3 with Impact on Abnormalities of Cardiac Structure/Function. *Sci. Rep.* 2019, 9, 5845. [CrossRef]

131. Mirzaei, M.; Pushpitha, K.; Deng, L.; Chitranshi, N.; Gupta, V.; Rajput, R.; Mangani, A.B.; Dheer, Y.; Godinez, A.; McKay, M.J.; et al. Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer’s Disease. *Mol. Neurobiol.* 2019, 56, 6017–6034. [CrossRef] [PubMed]

132. Mozhu, K.; Snively, B.M.; Rapp, S.R.; Wallace, R.B.; Williams, R.W.; Johnson, K.C. Genetic Analysis of Mitochondrial Ribosomal Proteins and Cognitive Aging in Postmenopausal Women. *Front. Genet.* 2017, 8. [CrossRef] [PubMed]

133. Ran, Q.; Xiang, Y.; Stephen, P.; Wu, C.; Li, T.; Lin, S.X.; Li, Z. CRIF1-CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity. *J. Am. Chem. Soc.* 2019, 141, 1420–1424. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).